Rapid-acting insulin analogues for the treatment of diabetes mellitus type 2: Executive summary of final report A05-04, Version 1.0

The aim of this benefit assessment was to compare the effects of long-term treatment with rapid-acting insulin analogues (RAIs) vs. short-acting regular human insulin (RHI) (and also compare the effects of different RAIs with each other) with regard to patient-relevant outcomes in patients with type 2 diabetes. In this text, the term “rapid-acting insulin analogues” (or “RAIs”) refers to all currently approved and available preparations of this type in Germany: insulin aspart, insulin glulisine, and insulin lispro. The term “short-acting insulin” refers to RHI; “longer-acting insulin” refers to intermediate-acting (e.g. Neutral Protamin Hagedorn [NPH]) and/or long-acting insulin (e.g. ultralente). This benefit assessment was conducted on the basis of the comparison and weighing of desired and undesired effects of the respective drugs (weighing of benefits and harms).